TELA Bio Inc.
TELA | NASDAQ
$1.31
+$0.01 (+0.77%)
Sep 22, 2026, 11:09 AM ET · Market open
Company Profile
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Key Executives
| Name | Position |
|---|---|
| Antony Koblish | Co-founder, Chief Executive Officer & Director |
| Heather C. Getz | CEO & Director |
| Paul Talmo | Chief Technology Officer |
| D. Taylor Ocasio | General Counsel & Corporate Secretary |
| Gregory A. Firestone | Chief Business Officer |
| Howard N. Langstein | Chief Medical Officer |
| Jeffrey Blizard | President |
| Jennifer Lou Armstrong | Senior Vice President of Human Resources |
| Jim Hagen | Senior VP of Strategic Commercial Operations & Marketing |
| Megan Smeykal | Vice President, Corporate Controller, Chief Accounting Officer & Principal Accounting Officer |
| Michael Leonard | Senior Vice President of Technical Operations |
| Roberto E. Cuca | CFO, Corporate Secretary & COO |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 04, 2026 | PRE 14A | Filing |
| Aug 31, 2026 | 8-K | Current Report |
| Aug 19, 2026 | 4 | Filing |
| Aug 17, 2026 | 4 | Filing |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 13, 2026 | 8-K/A | [Amend] Current Report |
| Aug 11, 2026 | S-8 | Filing |
| Aug 11, 2026 | 10-Q | Quarterly Report |
| Aug 11, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
TELA Bio Inc.
| Country | United States |
| IPO Date | Nov 6, 2019 |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Employees | 218 |
| CEO | Heather Getz |
Contact Details
1 Great Valley Parkway Malvern,
Pennsylvania 19355 United States
Stock Details
| Ticker Symbol | TELA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001561921 |
| CUSIP Number | 872381108 |
| ISIN Number | US8723811084 |
| SIC Code | 3841 |
Add to Watchlist
Select watchlists to add or remove TELA